Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07615309Enrolling by invitation
Omadacycline for Mycobacterium abscessus lung infection
This trial tests whether omadacycline (an antibiotic) can safely and effectively treat a rare lung infection caused by Mycobacterium abscessus bacteria. If you have this infection, this study may help doctors understand if this antibiotic works better than current treatments.
BeijingAges 18 years+ - NCT07619924Enrolling by invitationEarly Phase 1
Phage Cocktail for Hard-to-Treat Skin Infections
This study tests a new treatment called a phage cocktail (viruses that kill bacteria) for skin infections caused by bacteria that don't respond well to regular antibiotics. The treatment is applied directly to the wound to see if it's safe and effective.
Xi'an, ShaanxiAges 18–75 - NCT07620314RecruitingPhase 1
Testing a new cell therapy for B-cell lymphoma
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07620275RecruitingPhase 1
Cell therapy for multiple myeloma that has come back
This trial tests a new cell therapy (KSVCBD) for people with multiple myeloma that has returned or not responded to other treatments. It may help if your cancer cells have certain markers, CD19 or BCMA.
Beijing, Beijing MunicipalityAges 18–75 - NCT07614152RecruitingPhase 3
Growth hormone treatment for girls with Turner syndrome
This study tests whether a new long-acting growth hormone injection helps girls with Turner syndrome grow taller. Turner syndrome is a genetic condition that affects growth, and this trial will see if this treatment is safe and effective.
AnyangAges 2–12 - NCT07612280RecruitingPhase 1/Phase 2
Testing JBI-802 for blood cell disorders with high platelets
This study tests a new oral medication called JBI-802 to treat rare bone marrow disorders (myeloproliferative and myelodysplastic neoplasms) that cause abnormally high platelet counts. The goal is to evaluate whether the drug is safe and can help lower platelet levels and control disease.
Sydney, New South WalesAges 18 years+ - NCT07614191RecruitingEarly Phase 1
GT801 Cell Therapy for Hard-to-Treat Autoimmune Diseases
This early-stage study tests a new cell-based treatment called GT801 for autoimmune diseases that haven't responded well to standard medicines. It aims to see if this approach is safe and helps reduce symptoms in conditions like lupus, vasculitis, and scleroderma.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07616700RecruitingPhase 2
Long-term safety study of HSK39297 for IgA kidney disease
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
BeijingAges Any age - NCT07617597RecruitingPhase 3
Testing deuruxolitinib for severe hair loss in Japanese adults
This study tests whether a new drug called deuruxolitinib can help regrow hair in people with alopecia areata (an autoimmune condition causing patchy hair loss). The drug works by blocking certain immune signals that attack hair follicles.
AsahikawaAges 18–65 - NCT05484908Recruiting
Tested treatment for hepatitis B-related liver cancer after immunotherapy
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
Guangzhou, GuangdongAges 18–65 - NCT06707246Recruiting
Comparing secukinumab and tofacitinib for hidradenitis suppurativa
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hangzhou, ZhejiangAges 18–75 - NCT05745532RecruitingEarly Phase 1
Autologous stem cell treatment to improve beta thalassemia major
This early-phase trial tests a new way to restore working blood-making cells using your own stem cells for people with transfusion-dependent beta thalassemia major. The goal is to improve safety and blood results, and possibly reduce problems from the disease.
Shenzhen, GuangdongAges 8–16 - NCT05864170RecruitingEarly Phase 1
Tested injection for severe transfusion-dependent thalassemia
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
Shenzhen, GuangdongAges 18–35 - NCT05851105RecruitingEarly Phase 1
Study drug for severe alpha thalassemia in people needing regular transfusions
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
Nanning, GuangxiAges 12–35 - NCT07603752Recruiting
Brain implant to restore arm movement in spinal cord injury
This trial tests a wireless implant placed on the brain's surface to help people with cervical (neck-level) spinal cord injuries regain some arm and hand movement. The device reads brain signals and sends them to muscles, potentially bypassing the damaged spinal cord.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07606352RecruitingPhase 2
STL303 Safety and Efficacy for IgA Kidney Disease
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Newcastle, New South WalesAges 18 years+ - NCT07605845RecruitingPhase 1
Testing GL-2045 Safety in Immune Thrombocytopenia Patients
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
LeedsAges 18–80 - NCT07604805Recruiting
Chinese herbal medicine for severe lung blood pressure
This trial tests whether Qishen Yiqi Dropping Pills, a traditional Chinese herbal medicine, can safely improve symptoms and heart function in people with severe pulmonary hypertension (abnormally high blood pressure in the lungs). You would take this medicine alongside or instead of other treatments to see if it helps you walk farther and feel better.
Guangzhou, GuagdongAges 18–75 - NCT07608978RecruitingPhase 2
New drug combination for untreated aggressive lymphoma
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
Nanjing, JiangsuAges 18 years+ - NCT07604311RecruitingPhase 4
Preventing IgA nephropathy flare-ups with Nefecon
This study tests whether continuing Nefecon after initial treatment helps prevent IgA nephropathy (a kidney disease) from coming back. If you have already been on Nefecon for at least 9 months and your protein levels are low now, you might be able to join.
Guangzhou, GuangdongAges 18–75 - NCT07604896RecruitingPhase 4
Lecanemab for early Alzheimer's disease with amyloid buildup
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Wenzhou, ZhejiangAges 50–90 - NCT07608367Recruiting
Hydrogel glue for eye surface repair surgery
This trial tests a new hydrogel glue that may replace stitches during eye surface repair surgery. It could help your eye heal faster and more comfortably after procedures like pterygium removal or corneal repair.
Jinan, ShandongAges 18–85 - NCT07610551Recruiting
Combination therapy for advanced liver cancer
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
Xi’an, ShanxiAges 18 years+ - NCT06518005RecruitingPhase 2
Gene therapy for severe Crigler-Najjar syndrome
This trial tests a new gene therapy called GNT0003, given after a pre-treatment to help it work, for people with severe Crigler-Najjar syndrome. The goal is to see if it can reduce the need for daily light treatments.
ClamartAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.